$1.12 -0.02 (%) CTI BioPharma Corp -

Feb. 5, 2016 | 04:00 PM

Partner Headlines

  1. CTI BioPharma, Baxalta Complete Submission of NDA for Pacritinib for Unmet Medical Need In Myelofibrosis

    Benzinga | Jan. 5, 2016 | 04:15AM EST
  2. CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX®

    Benzinga | Dec. 14, 2015 | 04:08AM EST
  3. Analysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden

    Benzinga | Dec. 5, 2015 | 10:19AM EST
  4. Morning Market Gainers

    Benzinga | Nov. 23, 2015 | 09:44AM EST
  5. CTI BioPharma Initiates Rolling Submission of U.S. NDA for Pacritinib for Treatment of Patients with Myelofibrosis

    Benzinga | Nov. 23, 2015 | 04:10AM EST
  6. CTI BioPharma Announces Data Presentations at the 57th ASH Annual Meeting

    Benzinga | Nov. 6, 2015 | 04:19AM EST
  7. CTI BioPharma Prices Underwritten Public Offering of $50M of Convertible Preferred Stock

    Benzinga | Oct. 27, 2015 | 09:15AM EST
  8. CTI BioPharma, Fred Hutchinson Cancer Research Center Establish $1.5M Research Endowment Fund

    Benzinga | Oct. 1, 2015 | 04:29AM EST
  9. Monday Morning Pre-Market Insights: Celldex Therapeutics, Celladon Corp, CTI BioPharma Corp, TG ...

    GuruFocus | Jun. 1, 2015 | 17:15PM EST
  10. Morning Market Gainers

    Benzinga | Jun. 1, 2015 | 10:16AM EST
  11. Tuesday Morning Movers: ChannelAdvisor Plummets

    Benzinga | Jan. 13, 2015 | 09:29AM EST
  12. Incyte Building Blockbuster Drug One Disease At A Time

    IBD | Nov. 17, 2014 | 15:58PM EST
  13. Morning Market Movers

    Benzinga | Sep. 17, 2014 | 09:38AM EST
  14. Weekly CEO Sells Highlight: Groupon Inc., Cell Therapeutics Inc. ...

    GuruFocus | Mar. 24, 2014 | 11:12AM EST
  15. After-Hours Movers: BV, SWHC, AVAV, CTIC Moving Higher, HCI, BOBE, CHEF, THOR Lower

    Benzinga | Mar. 4, 2014 | 17:24PM EST
  16. Earnings Scheduled For March 4, 2014

    Benzinga | Mar. 4, 2014 | 04:35AM EST
  17. Mornings Movers for Feb. 27, 2014: PEIX, JCP, SYMX, CIE, SHLD, BBY Higher, INO, NDLS, HK, CY, DYAX Lower

    Benzinga | Feb. 27, 2014 | 09:43AM EST
  18. This Week's Sector Gainers And Losers

    Benzinga | Feb. 13, 2014 | 11:38AM EST
  19. Morning Market Losers

    Benzinga | Jan. 27, 2014 | 10:33AM EST
  20. Cell Therapeutics to Reacquire Rights to Two Anti-Cancer Compounds from Novartis

    Benzinga | Jan. 13, 2014 | 06:01AM EST
  21. Cell Therapeutics Announces Removal of Partial Clinical Hold on Tosedostat

    Benzinga | Jan. 2, 2014 | 07:19AM EST
  22. Cell Therapeutics Receives Remaining $5 million Under Existing Loan Financing Agreement

    Benzinga | Dec. 18, 2013 | 05:56AM EST
  23. Cell Therapeutics Presents Interim Results from Phase 2 Tosedostat Trial in Older Patients with AML or MDS at ASH

    Benzinga | Dec. 10, 2013 | 06:07AM EST
  24. Cell Therapeutics Announces Results from Preclinical Study of Pixantrone at AACR-NCI-EORTC Conference

    Benzinga | Oct. 21, 2013 | 06:26AM EST
  25. US Stock Futures Signal Lower Start On Wall Street

    Benzinga | Oct. 7, 2013 | 07:11AM EST
  26. Cell Therapeutics Reaches Agreement with FDA on SPA for Planned Pivotal Phase 3 Trial of Pacritinib in Myelofibrosis

    Benzinga | Oct. 7, 2013 | 05:56AM EST
  27. A Peek Into The Market Before The Trading Starts

    Benzinga | Dec. 10, 2012 | 00:21AM EST
  28. Ballots Are In: Worst CEO in the Biotech Industry Is . . .

    YCharts | Dec. 7, 2012 | 03:49AM EST
  29. Cell Therapeutics Says Study Achieved Endpoint Compared to Other Trials

    Benzinga | Dec. 5, 2012 | 11:04AM EST
  30. Cell Therapeutics Inc. Reports Operating Results (10-Q)

    GuruFocus | Nov. 1, 2012 | 13:34PM EST
  31. Will Cell Therapeutics Stay Above New-Found Support?

    SchaeffersResearch | Oct. 12, 2012 | 10:15AM EST
  32. Bears Set the Bar Low for Cell Therapeutics

    SchaeffersResearch | Oct. 5, 2012 | 11:06AM EST
  33. Cell Therapeutics Prices Offering at $1.40/Common Share

    Benzinga | Oct. 5, 2012 | 01:33AM EST
  34. Stocks End Mixed as Spanish Concerns Linger with General Motors (GM) and Chipotle Mexican Grill (CMG) on the Move

    MarketIntelligenceCenter | Oct. 2, 2012 | 16:27PM EST
  35. Morning Market Movers

    Benzinga | Oct. 2, 2012 | 04:08AM EST
  36. Cell Therapeutics Inc. (CTIC) President and CEO James A Bianco sells 10,000 Shares

    GuruFocus | Sep. 26, 2012 | 17:00PM EST
  37. Cell Therapeutics' Highly Selective Oral JAK 2 Inhibitor, Pacritinib, Demonstrates Encouraging Anti-tumor Activity

    Benzinga | Sep. 24, 2012 | 00:15AM EST
  38. Cell Therapeutics Inc. (CTIC) President and CEO James A Bianco sells 40,000 Shares

    GuruFocus | Sep. 21, 2012 | 17:00PM EST
  39. Highs & Lows: Cell Therapeutics, Toll Brothers, Travelers, and Valero Energy

    SchaeffersResearch | Sep. 11, 2012 | 14:55PM EST
  40. Morning Market Movers

    Benzinga | Sep. 11, 2012 | 03:48AM EST
  41. Cell Therapeutics Says Holders Approve SBio Transaction

    Benzinga | Aug. 31, 2012 | 10:16AM EST
  42. Hertz Global Holdings, Zalicus Among Stocks Gapping Up Monday

    FoxBusiness | Aug. 27, 2012 | 04:30AM EST
  43. Ubiquiti Networks, Office Depot Among Stocks falling to Annual Lows Monday

    FoxBusiness | Aug. 13, 2012 | 10:32AM EST
  44. Cell Therapeutics Inc. (CTIC) President and CEO James A Bianco sells 50,000 Shares

    GuruFocus | Aug. 10, 2012 | 15:19PM EST
  45. TreeHouse Foods, Alexco Resource Among Stocks hitting 52-Week Lows Thursday

    FoxBusiness | Aug. 9, 2012 | 06:32AM EST
  46. Cell Therapeutics Inc. Reports Operating Results (10-Q)

    GuruFocus | Aug. 2, 2012 | 16:24PM EST
  47. Cell Therapeutics Inc. (CTIC) President and CEO James A Bianco sells 50,000 Shares

    GuruFocus | Aug. 2, 2012 | 10:36AM EST
  48. Deckers Outdoor, Diamond Foods Among Stocks hitting 52-Week Lows Thursday

    FoxBusiness | Jun. 28, 2012 | 10:34AM EST
  49. Donaldson Company, Rovi Corporation Among Stocks falling to Annual Lows Friday

    FoxBusiness | Jun. 22, 2012 | 10:34AM EST
  50. Cell Therapeutics' Pixuvri Approved in European Union as Monotherapy to Treat Adult Patients with Multiply Relapsed or Refractory Aggressive Non-Hodgkin B-Cell Lymphomas

    Benzinga | May. 10, 2012 | 08:31AM EST
Trading Center